311 related articles for article (PubMed ID: 36358861)
1. Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies.
Sauter C; Simonet J; Guidez F; Dumétier B; Pernon B; Callanan M; Bastie JN; Aucagne R; Delva L
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358861
[TBL] [Abstract][Full Text] [Related]
2. The Role of Protein Arginine Methyltransferases in Pathogenesis and Treatment of Digestive System Carcinoma.
Wang B; Ding D; Zhang X; Zhang J; Zhang H; Liu X; Chang H; Gao Z; Yu Z
Mol Cancer Ther; 2023 Aug; 22(8):926-935. PubMed ID: 37141330
[TBL] [Abstract][Full Text] [Related]
3. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance.
Zhu Y; Xia T; Chen DQ; Xiong X; Shi L; Zuo Y; Xiao H; Liu L
Drug Resist Updat; 2024 Jan; 72():101016. PubMed ID: 37980859
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine methyltransferases (PRMTs): Orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance.
Gao Y; Feng C; Ma J; Yan Q
Biochem Pharmacol; 2024 Mar; 221():116048. PubMed ID: 38346542
[TBL] [Abstract][Full Text] [Related]
5. The macromolecular complexes of histones affect protein arginine methyltransferase activities.
Fulton MD; Cao M; Ho MC; Zhao X; Zheng YG
J Biol Chem; 2021 Oct; 297(4):101123. PubMed ID: 34492270
[TBL] [Abstract][Full Text] [Related]
6. Functional Study of
Lorenzon L; Quilles JC; Campagnaro GD; Azevedo Orsine L; Almeida L; Veras F; Miserani Magalhães RD; Alcoforado Diniz J; Rodrigues Ferreira T; Kaysel Cruz A
ACS Infect Dis; 2022 Mar; 8(3):516-532. PubMed ID: 35226477
[TBL] [Abstract][Full Text] [Related]
7. Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions.
Tong C; Chang X; Qu F; Bian J; Wang J; Li Z; Xu X
Eur J Med Chem; 2024 Mar; 267():116212. PubMed ID: 38359536
[TBL] [Abstract][Full Text] [Related]
8. Small Molecule Inhibitors of Protein Arginine Methyltransferases.
Hu H; Qian K; Ho MC; Zheng YG
Expert Opin Investig Drugs; 2016; 25(3):335-58. PubMed ID: 26789238
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic arginine methylation in breast cancer: emerging therapeutic strategies.
Wang SM; Dowhan DH; Muscat GEO
J Mol Endocrinol; 2019 Apr; 62(3):R223-R237. PubMed ID: 30620710
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses.
Fedoriw A; Shi L; O'Brien S; Smitheman KN; Wang Y; Hou J; Sherk C; Rajapurkar S; Laraio J; Williams LJ; Xu C; Han G; Feng Q; Bedford MT; Wang L; Barbash O; Kruger RG; Hwu P; Mohammad HP; Peng W
Cancer Immunol Res; 2022 Apr; 10(4):420-436. PubMed ID: 35181787
[TBL] [Abstract][Full Text] [Related]
11. A patent review of arginine methyltransferase inhibitors (2010-2018).
Li X; Wang C; Jiang H; Luo C
Expert Opin Ther Pat; 2019 Feb; 29(2):97-114. PubMed ID: 30640571
[TBL] [Abstract][Full Text] [Related]
12. The C. elegans PRMT-3 possesses a type III protein arginine methyltransferase activity.
Takahashi Y; Daitoku H; Yokoyama A; Nakayama K; Kim JD; Fukamizu A
J Recept Signal Transduct Res; 2011 Apr; 31(2):168-72. PubMed ID: 21385054
[TBL] [Abstract][Full Text] [Related]
13. Chemical probes and methods for the study of protein arginine methylation.
Brown T; Nguyen T; Zhou B; Zheng YG
RSC Chem Biol; 2023 Aug; 4(9):647-669. PubMed ID: 37654509
[TBL] [Abstract][Full Text] [Related]
14. Cellular pathways influenced by protein arginine methylation: Implications for cancer.
Xu J; Richard S
Mol Cell; 2021 Nov; 81(21):4357-4368. PubMed ID: 34619091
[TBL] [Abstract][Full Text] [Related]
15. Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer.
Shailesh H; Zakaria ZZ; Baiocchi R; Sif S
Oncotarget; 2018 Nov; 9(94):36705-36718. PubMed ID: 30613353
[TBL] [Abstract][Full Text] [Related]
16. Arginine methylation and respiratory disease.
Zhang B; Guan Y; Zeng D; Wang R
Transl Res; 2024 Mar; ():. PubMed ID: 38453053
[TBL] [Abstract][Full Text] [Related]
17. PRMT5 in gene regulation and hematologic malignancies.
Zhu F; Rui L
Genes Dis; 2019 Sep; 6(3):247-257. PubMed ID: 32042864
[TBL] [Abstract][Full Text] [Related]
18. Cancer synthetic vulnerabilities to protein arginine methyltransferase inhibitors.
Guccione E; Schwarz M; Di Tullio F; Mzoughi S
Curr Opin Pharmacol; 2021 Aug; 59():33-42. PubMed ID: 34052526
[TBL] [Abstract][Full Text] [Related]
19. Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer.
Liu S; Liu Z; Piao C; Zhang Z; Kong C; Yin L; Liu X
J Exp Clin Cancer Res; 2022 Oct; 41(1):293. PubMed ID: 36199122
[TBL] [Abstract][Full Text] [Related]
20. Genome wide comparative analysis of the effects of PRMT5 and PRMT4/CARM1 arginine methyltransferases on the Arabidopsis thaliana transcriptome.
Hernando CE; Sanchez SE; Mancini E; Yanovsky MJ
BMC Genomics; 2015 Mar; 16(1):192. PubMed ID: 25880665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
